Enhancing the understanding of doxorubicin's therapeutic impact in breast cancer.

Abstract

In this letter, we extend our commendation to the authors of the study titled "Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells" for their insightful work. However, we also propose several areas for potential enhancement. We identify the study's limitations, such as a focus on the effects of doxorubicin treatment over a limited 48-h period, potential biases due to algorithmic and database constraints, and the absence of in vivo model validation. We advocate for the application of machine learning to identify biomarkers, the use of molecular docking for target selection, and the incorporation of animal models and patient-derived samples to bolster the study's clinical significance. Our recommendations are intended to refine the research and deepen the comprehension of doxorubicin's therapeutic role in the treatment of breast cancer.